FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation

NCT05246618 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemia-reperfusion Injury
Kidney Transplant; Complications

Interventions

DRUG: TUM012
DRUG: Placebo

Sponsor

iCoat Medical AB

Collaborators

[object Object]
[object Object]